Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of antidiabetic drugs that have shown favorable effects in heart failure (HF) patients, irrespective the left ventricular ejection fraction (LVEF). Recent studies demonstrated beneficial empagliflozin on cardiac function and structure; however, less is known about dapagliflozin. The purpose current work was to invest...

Dapagliflozin is a novel sodium-glucose cotransporter type 2 inhibitor. This work aims to develop new validated sensitive RP-HPLC coupled with mass detector method for the determination of dapagliflozin, its alpha isomer, and starting material in presence dapagliflozin major degradation products an internal standard (empagliflozin). The separation was achieved on BDS Hypersil column (length 250...

INTRODUCTION The primary aim of this study is to compare the efficacy of three short-term glucose-lowering interventions (exercise, metformin and dapagliflozin) on glycaemic variability in overweight or obese men and women with elevated diabetes risk (ie, prediabetes, defined as haemoglobin A1c (HbA1c)39-47 mmol/mol / 5.7%-6.4%). The secondary aims are to investigate the effects of the interven...

BACKGROUND Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. METHODS A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2 diabetes mellitus, age >...

AIMS To investigate the association of novel oral glucose-lowering drugs (GLDs), compared with that of insulin, with risk of all-cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia. METHODS During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users of novel oral GLDs, either dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransport...

AIMS Greater reductions in glycated haemoglobin (HbA1c) with saxagliptin, a dipeptidyl peptidase-4 inhibitor, versus placebo add-on in patients with type 2 diabetes who had inadequate glycaemic control with dapagliflozin 10 mg/d plus metformin were demonstrated after 24 weeks of treatment. Results over 52 weeks of treatment were assessed in this analysis. MATERIALS AND METHODS Patients (mean ...

OBJECTIVE To evaluate whether adverse event reports to the US Food and Drug Administration on incidents of ketoacidosis from use of sodium glucose cotransport inhibitors (SGLT2 inhibitors) provide insight into ways this new class of drugs is being prescribed with other antihyperglycemic agents; to examine possible mechanisms to explain ketoacidosis. DESIGN AND METHODS Reports of adverse event...

BackgroundSodium-glucose cotransporter 2 (SGLT-2) inhibitors are currently used to treat patients with diabetes. Previous studies have demonstrated that treatment SGLT-2 is accompanied by altered metabolic phenotypes. However, it has not been investigated whether the hypothalamic circuit participates in development of compensatory phenotypes triggered inhibitors. MethodsMice were fed a standard...